IP Library Granted Patent US 10,550,146
Granted Patent B2
US 10,550,146 · App. 16/094,535 · Granted Feb 4, 2020

Methods for the preparation of obeticholic acid and derivatives thereof

Inventors: Benjamin List (Muelheim an de Ruhr, DE); Chandra Kanta De (Muelheim an der Ruhr, DE); Qinggang Wang (Qingdao, CN)
Assignee: Intercept Pharmaceuticals, Inc.
C07J9/005C07J9/00C07J31/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,550,146
App. No.
16/094,535
Granted
Feb 4, 2020
Kind
B2
Abstract

The present application relates to a safe method of preparing a bile acid derivative or a pharmaceutical acceptable salt, solvate, or amino acid conjugate thereof, on a large scale from 7-keto lithocholic acid (KLCA), comprising reacting Compound 2 with paraldehyde to form Compound 3 at a temperature between 10° C. and 30° C.:

Claims (27)

1. A method of preparing obeticholic acid (OCA)

or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, comprising:

a) reacting Compound 2 with paraldehyde to form Compound 3:

wherein the reaction is conducted at a temperature between 10° C. and 30° C.,

b) reacting Compound 3 with a base to form Compound 4:

c) hydrogenating Compound 4 to form Compound 5:

and

d) reducing the keto group at the C-7 position of Compound 5 to form OCA:

2. A method of claim 1 , wherein reacting Compound 2 with paraldehyde to form Compound 3 is conducted in the presence of a triflimide catalyst:

3. The method of claim 2 , wherein the triflimide catalyst is selected from (Tf) 2 NH, (Tf) 2 N—(C 1 -C 3 alkyl), and (Tf) 2 N-tri-C 1 -C 3 alkylsilyl.

4. The method of claim 3 , wherein the triflimide catalyst is (Tf) 2 N-trimethylsilyl.

5. The method of claim 1 , wherein the reaction of Compound 2 with paraldehyde to form Compound 3 is conducted in neat paraldehyde:

6. The method of claim 1 , wherein the molar ratio of paraldehyde to Compound 2 is between 3:1 and 6:1.

7. The method of claim 2 , wherein the reaction is conducted for 10 min to 4 hr.

8. The method of claim 1 , wherein Compound 3 is reacted with a base selected from metal hydroxide, C 1 -C 6 alkoxide, and metal hydride to form Compound 4:

9. The method of claim 8 , wherein the metal hydroxide is sodium hydroxide or potassium hydroxide.

10. The method of claim 9 , wherein the metal hydroxide is potassium hydroxide.

11. The method of claim 8 , wherein the reaction is conducted in a solvent selected from methanol, ethanol, propanol, isopropanol, water, and a mixture thereof.

12. The method of claim 11 , wherein the solvent is a mixture of ethanol and water, at an ethanol/water ratio of between 1:3 to 3:1 (vol/vol).

13. The method of claim 1 , wherein hydrogenating Compound 4 to form Compound 5 is conducted in the presence of a palladium catalyst:

14. The method of claim 1 , wherein reducing the keto group at the C-position of Compound 5 is conducted with sodium borohydride or sodium triacetoxyborohydride to form OCA:

15. The method of claim 1 , further comprising reacting Compound 1 with an alkyl silyl halide to form Compound 2:

16. The method of claim 15 , further comprising esterifying 7-keto lithocholic acid (KLCA) to form Compound 1:

17. The method of claim 12 , wherein the solvent is a mixture of ethanol and water, at an ethanol/water ratio of between 1:2 to 2:1 (vol/vol).

18. The method of claim 17 , wherein the solvent is a mixture of ethanol and water, at an ethanol/water ratio of between 1:1.5 to 1.5:1 (vol/vol).

19. The method of claim 18 , wherein the solvent is a mixture of ethanol and water, at an ethanol/water ratio of between 1:1.2 to 1.2:1 (vol/vol).

20. The method of claim 19 , wherein the solvent is a mixture of ethanol and water, at an ethanol/water ratio of between 1:1 to 1:1 (vol/vol).

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: LIST, BENJAMIN; DE, CHANDRA KANTA; WANG, QINGGANG
To: MAX-PLANCK-INSTITUT FUR HOHLENFORSCHUNG
Reel/Frame 048623/0274 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: MAX-PLANCK-INSTITUT FUR KOHLENFORSCHUNG
To: INTERCEPT PHARMACEUTICALS, INC
Reel/Frame 048623/0362 →
Continuity (2)
Provisional Application 62324405 · Apr 19, 2016
Related Publication 20190211052A1 · Jul 11, 2019